Otc - Active Ingredient
Bee Venom
Elaimei Bee Venom Cream
FDA Label NDC 83804-013
Full FDA labeling including Indications, Dosage, Usage, and Precautions
Structured Product Label
The following Structured Product Label (SPL) was submitted to the FDA by Shenzhen Shandian Jingling Technology Co., Ltd. for the product Elaimei Bee Venom Cream (NDC 83804-013). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding otc - active ingredient, otc - purpose, indications & usage, warnings, otc - do not use, otc - stop use, otc - when using, otc - keep out of reach of children, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Label Section Quick Index
Otc - Purpose
Relieve discomfort
Indications & Usage
ELAlMEl Bee Venom Cream is specially formulated tosupport joint comfort, promote healthy circulation, andenhance mobility. Made with a blend of powerful natura!ingredients, this cream helps soothe discomfort andsupports your active lifestyle.
Warnings
For external use only.
Otc - Do Not Use
Do not apply to broken or irritated skin.
Do not use if you areallergic to Bee Venom or any of the listed ingredientsIf irritation occurs, discontinue use and consult a
Otc - Stop Use
Do not use if you areallergic to Bee Venom or any of the listed ingredientsIf irritation occurs, discontinue use and consult a
Otc - When Using
For external use only. Avoid contact with eyes.
Otc - Keep Out Of Reach Of Children
Keep out of reach of children
Dosage & Administration
1. Clean and dry the affected area.
2. Apply a suitable amount and gently massage untilfully absorbed.
3. Use 2-3 times daily for better results.
Inactive Ingredient
Glucosamine
Methylsulfonylmethane (MSM)
Arnica Flower Extract
Chondroitin
Vitamin K2
Package Label.Principal Display Panel
Label (Label)
* Please review the disclaimer below.
